Immunotherapy using immune checkpoint inhibitors (ICI), including the programmed cell death protein 1 (PD-1), and its ligand programmed cell death ligand (PD-L1), has shown promising results in many different malignancies such as melanoma and lung cancer [20–22]. Here, PDCD1 is linked to lung carcinoma.